Camurus Ab (CAMRF) Q1 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

Thank you so much, Einar, and good day, everyone. Thank you for joining our first quarter earnings call. As previously, please note our forward-looking statements. So the agenda for today's call is as follows. We start with business highlights, followed by reviews of financial and commercial performance, then finish off with a short R&D update before moving over to Q&A. So as previously with me today are John Garay, our Chief Financial Officer, and Richard Jameson, Chief Commercial Officer. So overall, Canberra's had a productive and highly profitable first quarter 2025. This was driven by continuous commercial execution in Europe and Australia, strengthening our leadership position in opioid dependence treatment, Bividual sales increased to 485 million SEK, increasing 6% versus the previous year at constant exchange rate. Brixari royalties from the US increased 185% versus previous year, however, were flat versus previous quarter at CET. Notably, the overall buprenorphine OUD market in the US was down 13% during the same period. In the R&D pipeline, dosing was initiated in a phase one study of R1's monthly semaglutide. The phase three Sorrento-Positano studies of CAMP2029 in neuroendocrine tumors and polycystic liver disease progressed according to plan. And in addition, after the period, we received positive CHMP recommendation for approval of CAMP2029 in acromegaly in the EU. under the trade name Oxyisa. Financially, we had a strong first quarter with operating results growing 204% year on year to 239 million SEK. In parallel, we continued strengthening our sustainability profile, inaugurated our new headquarters in Lund and R&D laboratories. And after the period, we announced the appointment of Anders Wadsholt, as our next CFO, joining Camurus on the 1st of July,...